CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Gongwin Biopharm Holdings Co Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Gongwin Biopharm Holdings Co Ltd
3F, No. 80, Section 1
Jianguo North Road, Zhongshan District
Phone: +886 225035282p:+886 225035282 TAIPEI, 104  Taiwan Ticker: 66176617
Business Summary
Gongwin Biopharm Holdings Co Ltd is a company engaged in the research and development of anti-cancer medicine, especially focuses on the precise treatment to tumors. The Company’s headquarter is located in Taiwan and it created a cross-regional platform composed of Taiwan, China Mainland and the United States. The new PTS drug researched and developed by the Company is a new drug product for cancer treatment combined with minimally invasive interventional therapy technology, including PTS100 for the treatment of liver cancer, PTS302 for the treatment of lung cancer, PTS-02 for the treatment of rare diseases, PTS500 for the treatment of malignant pleural effusion and pets medication GWA101 and others.
(Source: N-30D)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202312/31/2023Yes----

Industries
SIC Code Description
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board Lester J.Wu 56 1/28/2016 1/28/2016
Chief Financial Officer, Corporate Governance Officer Wei NanHu 5/16/2023 6/29/2017
General Manager-Tianjin SiLiu 3/1/2022 3/1/2022
8 additional Officers and Directors records available in full report.

General Information
Outstanding Shares: 113,337,000 (As of 12/31/2023)
Shareholders: 6,404
Stock Exchange: TPO
Fax Number: +886 225035281


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, April 24, 2024